Prudentia Sciences provides a unified platform that centralizes internal and external drug data, applies expert‑crafted scientific diligence frameworks, and uses AI to generate evidence‑based assessments for licensing, M&A, and partnership decisions. The system enables corporate development, business development, and investment teams to screen, prioritize, and continuously re‑evaluate assets while mapping competitive landscapes and modeling valuation scenarios, all within a single, auditable workflow.
Funding
$7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
1OFounders
Product
Problem
Life‑science teams must evaluate an increasing number of drug assets for licensing, acquisition, or partnership, but their workflows are fragmented across multiple data sources, manual analyses, and disparate stakeholder inputs, leading to slow, inconsistent, and incomplete diligence.
Solution
Prudentia Sciences offers a unified platform that centralizes internal and external data, applies expert‑crafted scientific diligence frameworks, and leverages AI to generate evidence‑based assessments of drug assets. Users can screen opportunities, prioritize programs, and continuously re‑evaluate assets as new data emerge, all within a single system that links evaluation outcomes to source evidence. The platform also maps the competitive landscape, models valuation scenarios, and produces structured reports that support licensing, M&A, and partnership decisions. By automating routine analysis while keeping experts in the loop, Prudentia accelerates deal‑making without sacrificing rigor.
Target Audience
Primary users are corporate development, business development, and investment teams at pharmaceutical companies, biotech firms, and life‑science venture capital firms that need to evaluate drug assets efficiently and consistently.
Features
- Integrated data hub that ingests information from VDRs, CRMs, internal systems, and external datasets into a unified knowledge graph
- Expert‑designed scientific diligence frameworks tailored to asset biology, modality, and development stage
- AI‑driven reasoning engine that surfaces critical signals and generates evidence‑backed conclusions
- Continuous re‑assessment capability that updates evaluations as new data or signals become available
- Competitive‑landscape analytics that contextualize assets against therapeutic and market competitors in real time
- Valuation modeling tools that translate technical assessments into licensing, M&A, and partnership scenarios
- Centralized evidence repository linking every insight to its original source for auditability and transparency